Literature DB >> 12479512

Valvular heart disease in patients taking pergolide.

Allison M Pritchett1, John F Morrison, William D Edwards, Hartzell V Schaff, Heidi M Connolly, Raul E Espinosa.   

Abstract

OBJECTIVE: To determine whether an association exists between pergolide and valvular heart disease. PATIENTS AND METHODS: Three patients with severe, unexplained tricuspid regurgitation were examined at our institution from September 2000 to April 2002. Echocardiography and histology of surgically explanted valves revealed abnormalities suggestive of carcinoid involvement, methysergide or ergotamine treatment, or use of fenfluramine and dexfenfluramine. Carcinoid valvular heart disease was excluded. None of the patients had prior treatment with these drugs. All 3 patients were taking pergolide.
RESULTS: Of the 3 patients, 2 had predominantly right-sided congestive heart failure. In all 3 patients, echocardiography showed unusual valve morphology, with severe tricuspid valve regurgitation. Significant left-sided valve regurgitation was noted in 2 patients. Histologic analysis revealed surface fibroproliferative lesions with preserved underlying valve architecture.
CONCLUSION: The echocardiographic and histopathologic features of these cases are strikingly similar to those associated with carcinoid-, ergot-, and fenfluramine-induced valve disease. An association between pergolide and valvular heart disease may therefore exist.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12479512     DOI: 10.4065/77.12.1280

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  32 in total

1.  An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies.

Authors:  Miguel-Angel Maciá-Martínez; Francisco J de Abajo; Gilly Roberts; Jim Slattery; Bharat Thakrar; Antoni F Z Wisniewski
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

2.  Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease.

Authors:  Heinz Reichmann; Anja Bilsing; Reinhard Ehret; Wolfgang Greulich; Jörg B Schulz; Andreas Schwartz; Olivier Rascol
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

Review 3.  Pharmacologic resistance in prolactinoma patients.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

4.  The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.

Authors:  Nobuhiro Ooba; Takuhiro Yamaguchi; Kiyoshi Kubota
Journal:  Drug Saf       Date:  2011-04-01       Impact factor: 5.606

Review 5.  Heart failure induced by non-cardiac drugs.

Authors:  Lars Slørdal; Olav Spigset
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 6.  Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.

Authors:  Malcolm Steiger; W Jost; F Grandas; G Van Camp
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

Review 7.  Cardiovascular effects of noncardiovascular drugs.

Authors:  Satish R Raj; C Michael Stein; Pablo J Saavedra; Dan M Roden
Journal:  Circulation       Date:  2009-09-22       Impact factor: 29.690

8.  Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.

Authors:  D Dupuy; J P Lesbre; P Gérard; M Andrejak; O Godefroy
Journal:  J Neurol       Date:  2008-06-16       Impact factor: 4.849

9.  Benfluorex and unexplained valvular heart disease: a case-control study.

Authors:  Irène Frachon; Yves Etienne; Yannick Jobic; Grégoire Le Gal; Marc Humbert; Christophe Leroyer
Journal:  PLoS One       Date:  2010-04-12       Impact factor: 3.240

Review 10.  Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease.

Authors:  Terry-Elinor Reid; Krishna Kumar; Xiang Simon Wang
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.